ES2156162T3 - Compuestos activos en un nuevo sitio sobre canales del calcio accionados por un receptor, utiles para el tratamiento de trastornos y enfermedades neurologicas. - Google Patents
Compuestos activos en un nuevo sitio sobre canales del calcio accionados por un receptor, utiles para el tratamiento de trastornos y enfermedades neurologicas.Info
- Publication number
- ES2156162T3 ES2156162T3 ES94932057T ES94932057T ES2156162T3 ES 2156162 T3 ES2156162 T3 ES 2156162T3 ES 94932057 T ES94932057 T ES 94932057T ES 94932057 T ES94932057 T ES 94932057T ES 2156162 T3 ES2156162 T3 ES 2156162T3
- Authority
- ES
- Spain
- Prior art keywords
- receiver
- compound
- disorders
- useful
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 4
- 108090000312 Calcium Channels Proteins 0.000 title abstract 3
- 102000003922 Calcium Channels Human genes 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title abstract 3
- 230000000926 neurological effect Effects 0.000 title 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 2
- 208000025966 Neurological disease Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- MGRVRXRGTBOSHW-UHFFFAOYSA-N (aminomethyl)phosphonic acid Chemical compound NCP(O)(O)=O MGRVRXRGTBOSHW-UHFFFAOYSA-N 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 abstract 1
- 208000030886 Traumatic Brain injury Diseases 0.000 abstract 1
- 230000000202 analgesic effect Effects 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 239000002131 composite material Substances 0.000 abstract 1
- 229940125904 compound 1 Drugs 0.000 abstract 1
- 229940125782 compound 2 Drugs 0.000 abstract 1
- 229940126214 compound 3 Drugs 0.000 abstract 1
- 230000003412 degenerative effect Effects 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 238000002695 general anesthesia Methods 0.000 abstract 1
- 239000002555 ionophore Substances 0.000 abstract 1
- 230000003387 muscular Effects 0.000 abstract 1
- 230000036963 noncompetitive effect Effects 0.000 abstract 1
- 230000002040 relaxant effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/295—Iron group metal compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4462—Non condensed piperidines, e.g. piperocaine only substituted in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/22—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
- C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
Abstract
METODO PARA IDENTIFICAR UN COMPUESTO QUE SIRVA PARA EL TRATAMIENTO TERAPEUTICO DE UNA ENFERMEDAD NEUROLOGICA O DESORDEN TAL COMO INFARTO, TRAUMA CEREBRAL, DAÑO MEDULAR, EPILEPSIA, ANSIEDAD O ENFERMEDADES DEGENERATIVAS TALES COMO LAS ENFERMEDADES DE ALZHEIMER, DE HUNTINGTON O DE PARKINSON, O QUE SIRVA COMO RELAJANTE MUSCULAR, ANALGESICO O COADYUVANTE A LA ANESTESIA GENERAL. EL COMPUESTO ES ACTIVO EN UN CANAL DE CALCIO OPERADO POR EL RECEPTOR, QUE INCLUYE, PERO NO SE LIMITA, COMO ANTAGONISTA NO COMPETITIVO, AL QUE APARECE COMO PARTE DE UN COMPLEJO NMDA RECEPTOR-IONOFORO, AL RECEPTOR AMPA CALCIOPERMEABLE O A UN RECEPTOR NICOTINICO COLINERGICO. EL METODO CONSISTE EN IDENTIFICAR UN COMPUESTO QUE SE LIGA AL CANAL DE CALCIO OPERADO POR EL RECEPTOR EN EL LUGAR LIGADO POR EL COMPUESTO 1, COMPUESTO 2 O COMPUESTO 3 DE ARILALQUILAMINAS.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19421094A | 1994-02-08 | 1994-02-08 | |
US28866894A | 1994-08-09 | 1994-08-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2156162T3 true ES2156162T3 (es) | 2001-06-16 |
Family
ID=26889793
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES94932057T Expired - Lifetime ES2156162T3 (es) | 1994-02-08 | 1994-10-26 | Compuestos activos en un nuevo sitio sobre canales del calcio accionados por un receptor, utiles para el tratamiento de trastornos y enfermedades neurologicas. |
Country Status (15)
Country | Link |
---|---|
US (1) | US6306912B1 (es) |
EP (3) | EP1749522A3 (es) |
JP (6) | JPH09509484A (es) |
KR (1) | KR100366745B1 (es) |
CN (1) | CN1088585C (es) |
AT (2) | ATE346595T1 (es) |
AU (1) | AU710575B2 (es) |
CA (1) | CA2182680A1 (es) |
DE (2) | DE69434889D1 (es) |
DK (1) | DK0743853T3 (es) |
ES (1) | ES2156162T3 (es) |
GR (1) | GR3036215T3 (es) |
PT (1) | PT743853E (es) |
RU (1) | RU2201224C2 (es) |
WO (1) | WO1995021612A2 (es) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6071970A (en) * | 1993-02-08 | 2000-06-06 | Nps Pharmaceuticals, Inc. | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases |
US7087765B2 (en) | 1995-06-07 | 2006-08-08 | Nps Pharmaceuticals, Inc. | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases |
US6017965A (en) * | 1993-02-08 | 2000-01-25 | Nps Pharmaceuticals, Inc. | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases |
US6211245B1 (en) | 1993-02-08 | 2001-04-03 | Nps Pharmaceuticals, Inc. | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases |
US6750244B2 (en) | 1993-02-08 | 2004-06-15 | Nps Pharmaceuticals, Inc. | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases |
DE69434889D1 (de) * | 1994-02-08 | 2007-01-11 | Nps Pharma Inc | An einer neuen Stelle von Rezeptorabhängigen Kalziumkanälen wirkende Verbindungen zur Behandlung von neurologischen Erkrankungen |
DE4426245A1 (de) * | 1994-07-23 | 1996-02-22 | Gruenenthal Gmbh | 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung |
GB9611584D0 (en) * | 1996-06-04 | 1996-08-07 | Univ Edinburgh | Neurotransmitters |
WO1997046511A1 (en) * | 1996-06-07 | 1997-12-11 | Nps Pharmaceuticals, Inc. | Coumpounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases |
WO1998056752A1 (en) * | 1997-06-11 | 1998-12-17 | Nps Pharmaceuticals, Inc. | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases |
US6646149B1 (en) | 1997-07-15 | 2003-11-11 | Nicolaas M. J. Vermeulin | Polyamine analogues as therapeutic and diagnostic agents |
US7208528B1 (en) | 1997-07-15 | 2007-04-24 | Mediquest Therapeutics, Inc. | Polyamine analogues as therapeutic and diagnostic agents |
AU2003200048B2 (en) * | 1997-07-15 | 2005-12-15 | Mediquest Therapeutics, Inc. | Novel polyamine analogues as therapeutic and diagnostic agents |
WO1999003823A2 (en) * | 1997-07-15 | 1999-01-28 | Oridigm Corporation | Novel polyamine analogues as therapeutic and diagnostic agents |
EP1640359A3 (en) * | 1997-12-10 | 2006-04-05 | Nps Pharmaceuticals, Inc. | Anticonvulsant and central nervous system-active bis(fluorophenyl)alkylamides |
JP2001525390A (ja) * | 1997-12-10 | 2001-12-11 | エヌピーエス ファーマシューティカルズ インコーポレーテッド | 抗痙攣薬および中枢神経系活性ビス(フルオロフェニル)アルキルアミド類 |
US5981168A (en) | 1998-05-15 | 1999-11-09 | The University Of British Columbia | Method and composition for modulating amyloidosis |
CA2336962A1 (en) * | 1998-07-13 | 2000-01-20 | Alan Mueller | Methods and compounds for treating depression and other disorders |
JP2002527414A (ja) | 1998-10-14 | 2002-08-27 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | 1,2−ジ置換シクロプロパン |
WO2000075123A1 (en) * | 1999-06-04 | 2000-12-14 | Euro-Celtique S.A. | Substituted 5-oxo-5,6,7,8-tetrahydro-4h-1-benzopyrans and benzothiopyrans and the use thereof as potentiators of ampa |
US6680332B1 (en) | 1999-06-04 | 2004-01-20 | Euro-Celtique S.A. | Substituted 5-oxo-5,6,7,8-tetrahydro-4H-1-benzopyrans and benzothiopyrans and the use thereof as potentiators of AMPA |
USRE43327E1 (en) | 2001-01-08 | 2012-04-24 | Aminex Therapeutics, Inc. | Hydrophobic polyamine analogs and methods for their use |
AU2003220222A1 (en) | 2002-03-13 | 2003-09-29 | Signum Biosciences, Inc. | Modulation of protein methylation and phosphoprotein phosphate |
US20050159403A1 (en) * | 2003-04-22 | 2005-07-21 | Pharmacia Corporation | Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of central nervous system damage |
WO2004093813A2 (en) * | 2003-04-22 | 2004-11-04 | Pharmacia Corporation | Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of pain, inflammation or inflammation mediated disorders |
WO2006084033A1 (en) | 2005-02-03 | 2006-08-10 | Signum Biosciences, Inc. | Compositions and methods for enhancing cognitive function |
US7923041B2 (en) | 2005-02-03 | 2011-04-12 | Signum Biosciences, Inc. | Compositions and methods for enhancing cognitive function |
EP2282735B1 (en) * | 2008-04-21 | 2019-01-16 | Signum Biosciences, Inc. | Pp2a modulators for treating alzheimer, parkinson, diabetes |
CN101838235B (zh) * | 2009-06-12 | 2013-08-07 | 重庆华邦制药有限公司 | 3-苯基-3'-吡啶基丙烯胺类化合物及其合成方法 |
CN102267922B (zh) * | 2011-04-27 | 2014-11-19 | 中国人民解放军第三军医大学第一附属医院 | 一类多胺化合物及制备方法和用途 |
CN103394759B (zh) * | 2013-06-28 | 2016-09-21 | 南通恒鼎重型机床有限公司 | 一种管子旋槽机 |
US9840323B1 (en) | 2014-06-12 | 2017-12-12 | Kaiser Enterprises, Llc | Drone aircraft |
WO2017109709A2 (en) | 2015-12-22 | 2017-06-29 | Novartis Ag | A high-throughput assay method for identifying allosteric nmda receptor modulators |
KR102454783B1 (ko) | 2016-03-25 | 2022-10-13 | 아미넥스 테라퓨틱스, 인크. | 생체이용가능한 폴리아민 |
CN107056657B (zh) * | 2017-05-22 | 2019-04-26 | 湖南师范大学 | 一种昆虫特异性多胺类小分子毒素、其纯化方法及其应用 |
CN107311891B (zh) * | 2017-06-08 | 2019-08-06 | 山东一航新材料科技有限公司 | 一种亚胺类除水剂的制备方法 |
US20220280452A1 (en) * | 2019-06-26 | 2022-09-08 | The Regents Of The University Of California | Methods and compositions for treating smith-magenis syndrome |
US11358971B2 (en) | 2019-07-03 | 2022-06-14 | H. Lundbeck A/S | Prodrugs of modulators of the NMDA receptor |
US11466027B2 (en) | 2019-07-03 | 2022-10-11 | H. Lundbeck A/S | Modulators of the NMDA receptor |
CN111100097A (zh) * | 2019-12-04 | 2020-05-05 | 中国科学院高能物理研究所 | 二芳基甲烷类化合物及其制备方法 |
EP4221698A1 (en) | 2020-09-30 | 2023-08-09 | Aminex Therapeutics, Inc. | Combination drug substance of polyamine transport inhibitor and dfmo |
WO2022108507A1 (en) * | 2020-11-19 | 2022-05-27 | Weifeng Lin | Chemoselective probes and uses thereof |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE33285C (de) | G. HAMBRUCH in Berlin W., Behrenstr. 21 | Neuerungen an Schmiervorrichtungen | ||
NL300541A (es) * | ||||
GB191515827A (es) * | 1915-11-09 | 1916-10-19 | ||
DE1051281B (de) | 1955-07-05 | 1959-02-26 | Bayer Ag | Verfahren zur Herstellung von Derivaten der 1-Aryl-3-aminopropan-1-ole |
DE1099669B (de) * | 1958-07-31 | 1961-02-16 | Bayer Ag | Verfahren zur Herstellung von sauren Farbstoffen der Anthrachinonreihe |
DD33285A1 (es) * | 1963-02-16 | 1964-12-05 | ||
US3466236A (en) * | 1965-11-09 | 1969-09-09 | Eastman Kodak Co | Irradiation of aminocyclobutanones |
US3372193A (en) | 1966-06-01 | 1968-03-05 | Upjohn Co | 1, 1-diaryl-2-methyl-3-(benzylidene-amino) propan-(1)-ols |
GB1169944A (en) | 1966-08-25 | 1969-11-05 | Geistlich Soehne Ag | Novel 3,3-Diphenylpropylamines and processes for the preparation thereof |
FR2424253A1 (fr) | 1978-04-27 | 1979-11-23 | Brun Lab Sa Le | Nouveaux derives de peptides analogues des enkephalines, leur procede de preparation et leur application therapeutique |
DE3414240A1 (de) * | 1984-04-14 | 1985-10-17 | Basf Ag, 6700 Ludwigshafen | Verfahren zur herstellung von polyphenylenethern |
EP0208523A3 (en) * | 1985-07-08 | 1989-04-26 | Peter Norman Russell Usherwood | Glutamate antagonists |
DK258389D0 (da) | 1989-05-26 | 1989-05-26 | Ferrosan As | Aryloxyphenylpropylaminer, deres fremstilling og anvendelse |
US5037846A (en) * | 1990-01-02 | 1991-08-06 | Pfizer Inc. | Indolyl-3 polyamines and their use as antagonists of excitatory amino acid neurotransmitters |
US5312928A (en) | 1991-02-11 | 1994-05-17 | Cambridge Neuroscience | Calcium channel antagonists and methodology for their identification |
ATE312347T1 (de) * | 1991-08-23 | 2005-12-15 | Nps Pharma Inc | Screening-verfahren für kalzium-rezeptor aktive verbindungen |
HU9400503D0 (en) * | 1991-08-23 | 1994-05-30 | Pfizer | Synthetic aryl polyamines as excitatory amino acid neurotransmitter antagonists |
US5185369A (en) * | 1991-08-23 | 1993-02-09 | Pfizer Inc. | Synthetic heteroaryl polyamines as excitatory amino acid neurotransmitter antagonists |
DE4239816A1 (de) * | 1992-11-26 | 1994-06-01 | Inst Bioanalytik Ggmbh | Arzneimittel zur Behandlung des zentralen Nervensystems |
DE69434889D1 (de) * | 1994-02-08 | 2007-01-11 | Nps Pharma Inc | An einer neuen Stelle von Rezeptorabhängigen Kalziumkanälen wirkende Verbindungen zur Behandlung von neurologischen Erkrankungen |
DE4426245A1 (de) * | 1994-07-23 | 1996-02-22 | Gruenenthal Gmbh | 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung |
-
1994
- 1994-10-26 DE DE69434889T patent/DE69434889D1/de not_active Expired - Lifetime
- 1994-10-26 AT AT00121960T patent/ATE346595T1/de not_active IP Right Cessation
- 1994-10-26 EP EP06024225A patent/EP1749522A3/en not_active Ceased
- 1994-10-26 DK DK94932057T patent/DK0743853T3/da active
- 1994-10-26 KR KR1019960704290A patent/KR100366745B1/ko not_active IP Right Cessation
- 1994-10-26 EP EP00121960A patent/EP1123922B1/en not_active Expired - Lifetime
- 1994-10-26 AT AT94932057T patent/ATE200862T1/de not_active IP Right Cessation
- 1994-10-26 RU RU96118132/14A patent/RU2201224C2/ru not_active IP Right Cessation
- 1994-10-26 ES ES94932057T patent/ES2156162T3/es not_active Expired - Lifetime
- 1994-10-26 EP EP94932057A patent/EP0743853B1/en not_active Expired - Lifetime
- 1994-10-26 CA CA002182680A patent/CA2182680A1/en not_active Abandoned
- 1994-10-26 CN CN94195074A patent/CN1088585C/zh not_active Expired - Fee Related
- 1994-10-26 PT PT94932057T patent/PT743853E/pt unknown
- 1994-10-26 JP JP7521191A patent/JPH09509484A/ja active Pending
- 1994-10-26 AU AU80923/94A patent/AU710575B2/en not_active Ceased
- 1994-10-26 DE DE69427168T patent/DE69427168T2/de not_active Expired - Fee Related
- 1994-10-26 WO PCT/US1994/012293 patent/WO1995021612A2/en active IP Right Grant
-
1995
- 1995-06-07 US US08/483,294 patent/US6306912B1/en not_active Expired - Fee Related
-
2001
- 2001-07-13 GR GR20010401066T patent/GR3036215T3/el not_active IP Right Cessation
-
2003
- 2003-06-03 JP JP2003158350A patent/JP2004002437A/ja active Pending
-
2007
- 2007-07-19 JP JP2007188835A patent/JP2007314556A/ja active Pending
-
2008
- 2008-12-25 JP JP2008331256A patent/JP2009143927A/ja active Pending
-
2012
- 2012-01-05 JP JP2012000548A patent/JP2012102130A/ja active Pending
-
2014
- 2014-01-16 JP JP2014005535A patent/JP2014166987A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AU710575B2 (en) | 1999-09-23 |
EP1123922A2 (en) | 2001-08-16 |
DE69434889D1 (de) | 2007-01-11 |
JP2004002437A (ja) | 2004-01-08 |
KR100366745B1 (ko) | 2003-04-18 |
EP1749522A2 (en) | 2007-02-07 |
JP2009143927A (ja) | 2009-07-02 |
EP1123922B1 (en) | 2006-11-29 |
DE69427168T2 (de) | 2002-01-24 |
RU2201224C2 (ru) | 2003-03-27 |
DK0743853T3 (da) | 2001-07-16 |
DE69427168D1 (de) | 2001-06-07 |
CN1088585C (zh) | 2002-08-07 |
ATE200862T1 (de) | 2001-05-15 |
ATE346595T1 (de) | 2006-12-15 |
WO1995021612A3 (en) | 1995-09-21 |
JP2012102130A (ja) | 2012-05-31 |
AU8092394A (en) | 1995-08-29 |
JP2007314556A (ja) | 2007-12-06 |
JP2014166987A (ja) | 2014-09-11 |
EP0743853B1 (en) | 2001-05-02 |
CA2182680A1 (en) | 1995-08-17 |
PT743853E (pt) | 2001-10-31 |
EP1123922A3 (en) | 2004-01-02 |
WO1995021612A2 (en) | 1995-08-17 |
US6306912B1 (en) | 2001-10-23 |
CN1148337A (zh) | 1997-04-23 |
GR3036215T3 (en) | 2001-10-31 |
JPH09509484A (ja) | 1997-09-22 |
EP0743853A1 (en) | 1996-11-27 |
EP1749522A3 (en) | 2010-10-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2156162T3 (es) | Compuestos activos en un nuevo sitio sobre canales del calcio accionados por un receptor, utiles para el tratamiento de trastornos y enfermedades neurologicas. | |
BR0307919A (pt) | Sais de topiramato e composições compreendendo-os e métodos para sua fabricação e uso | |
ATE355374T1 (de) | Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen | |
PT1326613E (pt) | Utilizacao de derivados de imidazo[1,2-a]piridin-,imidazo[1,2-a]pirimidin- e imidazo[1,2-a]pirazin-3-il-amina substituidos para a fabricacao de medicamentos para inibicao de nos | |
BR0214825A (pt) | Uréias de 2-aminobenzotiazóis como moduladores de adenosina | |
BR0205722A (pt) | Formulação de liberação prolongada e método para o tratamento de um paciente que sofre de dor | |
ECSP066730A (es) | Compuestos y procedimientos para uso | |
CY1105507T1 (el) | Υποκατεστημενες πυραζολο- και θειαζολοπυριμιδινες | |
ECSP034655A (es) | Composiciones farmaceuticas de un agonista del receptor de nmda | |
HK1008980A1 (en) | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders | |
HUP9904525A2 (hu) | S-(-)-N-Propargil-1-amino-indán tartalmú neurológiai rendellenességek kezelésére alkalmas gyógyszerkészítmények | |
CO5261590A1 (es) | Un derivado de pirrolidinacetamida solo o en combinacion para el tratamineto de transtornos del sistema nervioso central (cns) | |
DE19525598A1 (de) | Schlafmittel | |
KR20090018817A (ko) | 인지 장애의 치료에 유용한 알파-아미노아미드 유도체 | |
HK1092358A1 (en) | Method for producing medicaments for reducing amyloid deposition, amyloid neurotoxicity and microgloisis | |
UY27023A1 (es) | Derivados de fenil cetonas sustituidas como antagonistas de ip | |
PA8540701A1 (es) | Uso de agonistas inversos de gabaa en combinacion con agonistas parciales del receptor de nicotina, estrogenos, moduladores selectivos de estrogenos o vitamina e, para el tratamiento de trastornos cognitivos | |
ES2168309T3 (es) | Efectos neuroprotectores primario y secundario de la flupirtina en las enfermedades neurodegenerativas. | |
DOP2002000356A (es) | Conjugados de pregabalina lactosa | |
NZ525417A (en) | Substituted 5-amino-1-pentene-3-ol derivatives | |
NZ598861A (en) | Role of n-2 hydroxy-ethyl-piperazine-n'-2-ethane sulfonic acid (hepes) in pain control and reversal of demyelinization injury | |
AR036007A1 (es) | Compuesto del acido 2-[(2's)-(2'-amino)-propionil]amino-biciclo[3.1.0]hexano-2,6-dicarboxilico, sal farmaceuticamente aceptable del mismo, formulacion farmaceutica que lo comprende, proceso para preparar dicho compuesto, metodo para afectar los receptores de glutamato metabotropicos unidos-camp en u | |
AR026804A1 (es) | Utilizacion de la enoxaparina para la preparacion de un medicamento para tratar la isquemia cerebral | |
Brandt | Schwindel | |
CR7060A (es) | Conjugados de pregabalina-lactosa |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 743853 Country of ref document: ES |